The 2027 contract cycle is being written under pressure that didn't exist when the last one was signed. Tariff exposure, GPO consolidation, reimbursement moving from pilot to policy.
A closed-door working session for the director- and EVP-level medtech leaders who actually write and negotiate these contracts — at companies like yours. This is the room where that gets worked through, not presented at.
No buyers. No press. No sales pitch.
Seats are personally allocated. Maximum two per company.
Across the US market, the commercial terms that will govern 2027 are being drafted right now — against tariff exposure that was theoretical eighteen months ago, GPO structures that have consolidated buying power, and reimbursement frameworks moving from pilot to policy. The people holding the pen are commercial and pricing directors, heads of tender and bids, contract and revenue-operations leaders. They are making these calls largely without a peer forum.
No existing US event owns this conversation. Policy conferences treat pricing as a regulatory question. Innovation summits skip contracting altogether. Where supplier-side content does appear, it is typically sponsor-hosted — which changes what can honestly be said in the room.
The timing is deliberate. December 2 lands after the year's major US medtech gatherings have wrapped, and well after the Section 232 medical-device tariff decision. The room reacts to confirmed policy outcomes and a full year of takeaways from the field — not to speculation.
The session is built on Vamstar's Commercial research base and data: 48 verified findings drawn from 222 referenced sources on US medtech pricing and contracting. That research frames the discussion. It is not the subject of it — the room is.
A keynote to frame, a policy briefing to ground, a working session to actually do the work, and a closing round where everyone commits to something. Reception and dinner follow.
How contract structure absorbs shocks that pricing alone cannot. Drawn from Vamstar's Commercial research base and data.
A grounded read on the medical-device tariff decision and its direct consequences for commercial terms in the 2027 cycle.
The gap between winning the award and realising the revenue. Open working format, full group.
Each participant leaves with three commitments they can act on inside their own organisation.
Agenda is indicative and not yet committed. Final timings and the remaining speaker confirmed on acceptance.
Invitations are extended personally, based on how directly each participant's remit touches the questions under discussion. The group is deliberately small and deliberately one-sided — supplier-side only. Both are necessary conditions for the conversation to be worth having.
Seats are allocated by relevance rather than by response order. The value of the day rests entirely on who is in the room — people close enough to the same pressures to say something useful about them.
Keeping buyers out is the other half of that. Commercial and pricing leaders cannot speak plainly about tariff pass-through, GPO leverage, or gross-to-net reality with the counterparty listening.
Vamstar convenes the session and brings the research. We will also say something about our own work before the day closes — briefly, and flagged as such, separate from the working sessions. The rest of the room belongs to the room.
This session is convened by Vamstar, whose work in commercial intelligence and pricing strategy across health systems produced the research base behind the agenda. Vamstar contributes that research as one input to the peer conversation. Not as the subject of it.
Source: The Commercial Crucible — US MedTech Pricing & Contracting in 2026 (Polaris research base, Vamstar).
Five fields. Seats are allocated by relevance rather than by response order, so being early doesn't help — but being the right person does.
Tim Farnham will come back to you within two working days, either with a seat and the venue details, or with a straight answer if the room is already full. If it's urgent, reply directly to timothy.farnham@vamstar.io.
Seats are personally allocated, not assigned by response order. Maximum two per company. Prefer email? Write to timothy.farnham@vamstar.io.